Nuclear Medicine Leader Dr. M. Donald Blaufox Leads Cell Point Cancer Diagnostic Phase 2/3 Trial

CENTENNIAL, Colo. (SEND2PRESS NEWSWIRE) — Cell>Point announced today that M. Donald Blaufox, M.D., Ph.D, will be coordinating principal investigator for its Phase 2/3 clinical trial of 99mTc-EC-G for cancer diagnostic imaging. The trial is currently underway. 99mTc-EC-G is the company’s cancer diagnostic imaging agent, an acronym for 99mTechnetium-EthylenediCysteine-Glucosamine.